沙利度胺诱发的多发性骨髓瘤患者银屑病。
Psoriasis induced by thalidomide in a patient with multiple myeloma.
作者信息
Ferrazzi Anna, Zambello Renato, Russo Irene, Alaibac Mauro
机构信息
Unit of Dermatology, University of Padua, Padova, Italy.
Unit of Hematology, University of Padua, Padova, Italy.
出版信息
BMJ Case Rep. 2014 Jun 27;2014:bcr2014204469. doi: 10.1136/bcr-2014-204469.
A 54-year-old woman developed psoriasis on the plantar surface of her feet after 2 weeks of thalidomide 100 mg daily for the treatment of multiple IgG myeloma. She did not have any previous history of psoriasis. Thalidomide was immediately stopped and topical treatment with calcipotriol ointment and β-methasone valerate was started. Psoriasis disappeared completely after 2 weeks of topical therapy. This is the first case of de novo psoriasis in a patient with multiple myeloma under treatment with thalidomide. Our observation provides further evidence of the potential paradoxical effect of thalidomide on tumour necrosis factor-α production.
一名54岁女性，在每日服用100mg沙利度胺治疗多发性IgG骨髓瘤2周后，足底出现银屑病。她既往无银屑病病史。沙利度胺立即停用，并开始外用卡泊三醇软膏和戊酸倍他米松治疗。局部治疗2周后银屑病完全消失。这是首例在接受沙利度胺治疗的多发性骨髓瘤患者中出现的新发银屑病病例。我们的观察为沙利度胺对肿瘤坏死因子-α产生的潜在矛盾效应提供了进一步证据。
Zotero 插件